These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Clinical and biochemical study of d-serine metabolism among schizophrenia patients. El-Tallawy HN; Saleem TH; El-Ebidi AM; Hassan MH; Gabra RH; Farghaly WM; Abo El-Maali N; Sherkawy HS Neuropsychiatr Dis Treat; 2017; 13():1057-1063. PubMed ID: 28435276 [TBL] [Abstract][Full Text] [Related]
43. Identification of a novel spinal dorsal horn astroglial D-amino acid oxidase-hydrogen peroxide pathway involved in morphine antinociceptive tolerance. Gong N; Li XY; Xiao Q; Wang YX Anesthesiology; 2014 Apr; 120(4):962-75. PubMed ID: 23928652 [TBL] [Abstract][Full Text] [Related]
44. Contributions of spinal D-amino acid oxidase to bone cancer pain. Huang JL; Chen XL; Guo C; Wang YX Amino Acids; 2012 Nov; 43(5):1905-18. PubMed ID: 22996731 [TBL] [Abstract][Full Text] [Related]
45. Novel insights into renal D-amino acid oxidase accumulation: propiverine changes DAAO localization and peroxisomal size in vivo. Luks L; Sacchi S; Pollegioni L; Dietrich DR Arch Toxicol; 2017 Jan; 91(1):427-437. PubMed ID: 26961980 [TBL] [Abstract][Full Text] [Related]
46. Effects of lead exposure on D-serine metabolism in the hippocampus of mice at the early developmental stages. Yu H; Li T; Cui Y; Liao Y; Wang G; Gao L; Zhao F; Jin Y Toxicology; 2014 Nov; 325():189-99. PubMed ID: 25242007 [TBL] [Abstract][Full Text] [Related]
47. D-Serine metabolism: new insights into the modulation of D-amino acid oxidase activity. Sacchi S Biochem Soc Trans; 2013 Dec; 41(6):1551-6. PubMed ID: 24256253 [TBL] [Abstract][Full Text] [Related]
48. d-Serine and d-Alanine Regulate Adaptive Foraging Behavior in Saitoh Y; Katane M; Miyamoto T; Sekine M; Sakai-Kato K; Homma H J Neurosci; 2020 Sep; 40(39):7531-7544. PubMed ID: 32855271 [TBL] [Abstract][Full Text] [Related]
49. Discovery of a Novel Class of d-Amino Acid Oxidase Inhibitors Using the Schrödinger Computational Platform. Tang H; Jensen K; Houang E; McRobb FM; Bhat S; Svensson M; Bochevarov A; Day T; Dahlgren MK; Bell JA; Frye L; Skene RJ; Lewis JH; Osborne JD; Tierney JP; Gordon JA; Palomero MA; Gallati C; Chapman RSL; Jones DR; Hirst KL; Sephton M; Chauhan A; Sharpe A; Tardia P; Dechaux EA; Taylor A; Waddell RD; Valentine A; Janssens HB; Aziz O; Bloomfield DE; Ladha S; Fraser IJ; Ellard JM J Med Chem; 2022 May; 65(9):6775-6802. PubMed ID: 35482677 [TBL] [Abstract][Full Text] [Related]
50. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Hashimoto K; Fujita Y; Horio M; Kunitachi S; Iyo M; Ferraris D; Tsukamoto T Biol Psychiatry; 2009 Jun; 65(12):1103-6. PubMed ID: 19217074 [TBL] [Abstract][Full Text] [Related]
51. D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase. Wu M; Zhou XJ; Konno R; Wang YX Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1042-6. PubMed ID: 17042912 [TBL] [Abstract][Full Text] [Related]
52. Comments on 'The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia'. Hashimoto K J Psychopharmacol; 2010 Jul; 24(7):1133-4. PubMed ID: 19939869 [No Abstract] [Full Text] [Related]
53. INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia. Murthy V; Hanson E; DeMartinis N; Asgharnejad M; Dong C; Evans R; Ge T; Dunayevich E; Singh JB; Ratti E; Galderisi S Schizophr Res; 2024 Aug; 270():249-257. PubMed ID: 38943928 [TBL] [Abstract][Full Text] [Related]
54. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors. Labrie V; Clapcote SJ; Roder JC Pharmacol Biochem Behav; 2009 Feb; 91(4):610-20. PubMed ID: 18940194 [TBL] [Abstract][Full Text] [Related]
55. Is endogenous D-serine in the rostral anterior cingulate cortex necessary for pain-related negative affect? Ren WH; Guo JD; Cao H; Wang H; Wang PF; Sha H; Ji RR; Zhao ZQ; Zhang YQ J Neurochem; 2006 Mar; 96(6):1636-47. PubMed ID: 16476080 [TBL] [Abstract][Full Text] [Related]
57. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Uezato A; Meador-Woodruff JH; McCullumsmith RE Bipolar Disord; 2009 Nov; 11(7):711-25. PubMed ID: 19839996 [TBL] [Abstract][Full Text] [Related]
58. Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Lin CH; Chen YM; Lane HY Curr Drug Targets; 2020; 21(6):610-615. PubMed ID: 31660823 [TBL] [Abstract][Full Text] [Related]
59. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Yang CR; Svensson KA Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436 [TBL] [Abstract][Full Text] [Related]
60. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]